Serum bcl-2 antigen (ELISA)  
  Total No.   (%) Positive bcl-2 No.     (%) Negative bcl-2 No.     (%) P. value
Mean Age ± SD 49.9 ± 2.96 48.5 ± 12.8 50.6 ± 13.4 0.88
Sex   0.1
Male 29 (64.4%) 6   (20.7%) 23   (79.3%)
Female 16 (35.6%) 7   (43.7%) 9    (56.3%)
Size   0.19
<5 17  (37.8%) 3   (17.6%) 14   (82.4%)
>5 28  (62.2%) 10   (35.7%) 18   (64.3%)
Site   0.17
Antrum 25  (55.6%) 8   (32.0%) 17  (68.0%)
Body 13  (28.9%) 4   (30.8%) 9    (69.2%)
Cardia 7   (15.6%) 1   (14.3%) 6    (85.7%)
Gross (shape)   0.19
Ulcerating 27  (60.0%) 8   (32.0%) 19  (70.4%)
Infiltrating 9   (20.0%) 4   (30.8%) 8   (88.9%)
Polypoi 9   (20.0%) 1   (14.3%) 5   (55.6%)
Type       0.8
Epithelial tumor 37  (82.2%) 8   (29.6%) 27   (73.0%)
Stromal tumor 3   (06.7%) 1   (11.1%) 1   (33.3%)
NHL 5   (11.1%) 4   (44.4%) 4   (40.0%)
Grade   0.12
Low 10  (22.2%) 3   (30.0%) 7   (70.0%)
Intermediate 23  (51.1%) 4   (17.4%) 19   (82.6%)
High 12    (26.7%) 6   (50.0%) 6   (50.0%)
Total 45 (100%) 13 (28.9%) 32 (71.1%)  
Table 1: Clinicopathological parameters against serum Bcl-2 antigen by ELSIA.